Coronavirus: while we keep social distance, we fight back with knowledge sharing
OniX is sharing information daily about the coronavirus to keep the public and researchers up-to-date. We are also reaching out to potential sponsors to provide OniX available free for all researchers - we'll let you know when we will be able to do that. We will provide e-alerts and access to the OniX portal with funded grants, startups, biotech companies, clinical trials, and news about COVID-19.
In the meantime, here are some of the latest research and news that we have been posting online:
Effective Treatment of Severe COVID-19 Patients with Tocilizumab chinaxiv.org Background: In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was ident…
Japanese flu drug 'clearly effective' in treating coronavirus, says China Japanese flu drug 'clearly effective' in treating coronavirus, says China
Tracking the Coronavirus: How Crowded Asian Cities Tackled an Epidemic: Singapore, Taiwan and Hong Kong offer successful strategies, at least so far, in battling a pandemic. But they use tactics that the U.S. and Europe may not be able to replicate.
Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2): high proportion of undocumented infections, many of whom were likely not severely symptomatic, appears to have facilitated the rapid spread of the virus throughout China https://lnkd.in/euq3rR7
Covid-19 Patient Helps Scientists Map Virus Immune Response: study provides novel contributions to the understanding of the breadth and kinetics of immune responses during a non-severe case of COVID-19. Furthermore, study indicates that robust multi-factorial immune responses can be elicited to the newly emerged virus SARS-CoV-2 and, similar to the avian H7N9 disease8, early adaptive immune responses might correlate with better clinical outcomes.
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Gasdermin E: A new approach to cancer immunotherapy that could have broad reach: tumour GSDME ( also known as DFNA5) acts as a tumour suppressor by activating pyroptosis, enhancing anti-tumour immunity. https://lnkd.in/diczau3
Investigators Identify 2 Circulating SARS-CoV-2 Strains: urgent need for further immediate, comprehensive studies that combine genomic data, epidemiological data, and chart records of the clinical symptoms of patients with coronavirus disease 2019 (COVID-19) https://lnkd.in/dUTAzjy
Cell therapy could treat respiratory effects caused by coronavirus - https://lnkd.in/dqKGKjy
Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus - https://lnkd.in/dGWBChy
Could stem cells help patients with coronavirus disease COVID-19? Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia - https://lnkd.in/dzXGuh9
Coronavirus Infections in Children Including COVID-19 - https://lnkd.in/dEqPvQp-
Detection of Covid-19 in Children in Early January 2020 in Wuhan, China https://lnkd.in/d6xpz9K
Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding - https://lnkd.in/djtpqBS
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study: The longest observed duration of viral shedding in survivors was 37 days. https://lnkd.in/e2HKy7D
Flu and Coronavirus: Similar Symptoms, Different Fears https://lnkd.in/d5vZJ6p
How Coronavirus Hijacks Your Cells: The virus that causes Covid-19 is currently spreading around the world. At least six other types of coronavirus are known to infect humans, with some causing the common cold and two causing epidemics: SARS in 2002 and MERS in 2012
Israeli scientists: 'In a few weeks, we will have coronavirus vaccine':Once the vaccine is developed, it will take at least 90 days to complete the regulatory process and potentially more to enter the marketplace. Israeli scientists: 'In a few weeks, we will have coronavirus vaccine' jpost.com
You can find links to all these articles on my linkedIn page
OniX supports the research enterprise by providing an one-stop research knowledge hub that includes non-confidential technology summaries of funded and unfunded grants applications/ideas from government and private foundations; technology transfer assets from universities, government and others; startups, incubators and biotechnology companies non-confidential technology summaries. In addition, we provide access to journal publications, patents, clinical trials and news
OniX can support the ongoing efforts to accelerate vaccines, diagnostics and treatments for the coronavirus, as well as, to stay up-to-the minute of any news and discoveries via OniX e-mail alerts.
Please reach out to find out how we can help or if you would like to be a sponsor at firstname.lastname@example.org